Halozyme Therapeutics | HALO - Interest Expense On Debt


Halozyme Therapeutics reported $5.51M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.18B 4.3B Mar/2026
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
Amarin USD 3K 5K Dec/2024
Amgen USD 657M 4M Mar/2026
Baxter International USD 58M 14M Sep/2025
Cara Therapeutics -89.64M 128.67M Dec/2025
Cytokinetics USD 33.34M 3M Mar/2026
DBV Technologies USD 461K 323.71K Mar/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Esperion Therapeutics USD 22.64M 585K Dec/2025
Halozyme Therapeutics USD 5.51M 597K Mar/2026
Intrexon USD 2K 5K Jun/2024
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
MannKind USD 12.43M 1.44M Mar/2026
Minerva Neurosciences USD 2.31M 60K Jun/2024
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Pfizer USD 671M 40M Mar/2026
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
United Therapeutics USD 3.1M 100K Dec/2025
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025